The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
Featured:
Raphael ItzyksonDuring the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Raphael Itzykson, Université de Paris, Paris, FR, about the phase III Dacota trial. We asked, Will hydroxyurea remain standard of care for advanced proliferative chronic myelomonocytic leukemia (CMML)?
Phase III Dacota trial: Will hydroxyurea remain SoC for advanced proliferative CMML?
Itzykson discusses the results from the randomized phase III Dacota trial evaluating decitabine versus hydroxyurea in patients with advanced proliferative CMML.